Deloitte’s 2026 Life Sciences Outlook points to an industry that remains confident in its own growth prospects while far less certain about the broader environment. More than three-quarters
The report suggests that this gap is shaping strategy for the year ahead, as companies balance investment in AI, digital transformation, and pipeline expansion against a more fragmented backdrop of regulatory change, pricing pressure, and geopolitical risk. Regional differences are also notable: surveyed biopharma executives in Europe and Asia were markedly more upbeat than their U.S. peers, while medtech leaders reported relatively strong expectations across geographies.
The report also shows life sciences leaders placing greater weight on execution. Nearly half of respondents said accelerated digital transformation would materially affect strategy in 2026, and 41% cited generative AI as a major influence, though only a small minority said their organizations had successfully scaled AI or generated significant returns from it. Cost discipline is emerging as a parallel priority, with executives focused on productivity, pricing and access, and more selective portfolio decisions.
At the same time, growth plans remain active: roughly half of surveyed biopharma and medtech executives said launching new therapies, devices, or platforms would be a core focus, while interest in mergers and acquisitions has moved higher on the agenda. Deloitte’s broader message is that 2026 will reward companies that can combine innovation with operational resilience, rather than treating them as separate priorities.